A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TORL-2-307-ADC (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms TRIO052
Sponsors TORL Biotherapeutics

10 Sep 2024 According to a TORL BioTherapeutics media release, company is currently open to enrollment for the expansion portion, Part 2, assessing the safety, pharmacokinetics, biomarkers, and antitumor activity of TORL-2-307ADC.
10 Apr 2024 According to a TORL BioTherapeutics media release, company announced $158M Series B-2 Financing led by Deep Track Capital.Proceeds from this Series B-2 financing will be used to continue the clinical development of this trial.
09 Jan 2024 According to a TORL Biotherapeutics media release, company is currently enrolling patients in the expansion portion of this phase 1 study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com